🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Steven Fletcher

University of Maryland, Baltimore

ORCID: 0000-0002-4429-8334

Also affiliated with University of Maryland Medical System

Biochemistry, Genetics and Molecular BiologyMedicineChemistry

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 15 papers. Top paper: “VLA4-Targeted Nanoparticles Hijack Cell Adhesion–Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong Survival”.

VLA4-Targeted Nanoparticles Hijack Cell Adhesion–Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong Survival

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2839

N/A

0.948DataRank · unranked

27 citations

Michael J. Scott, John S. Allen, Xiaoxia Yang, Grace Cui, Dipanjan Pan +12 more

Shifting the paradigm in treating multi-factorial diseases: polypharmacological co-inhibitors of HDAC6

RSC Medicinal Chemistry(2020)10.1039/d0md00286k

N/A

0DataRank · unranked

12 citations

Steven Fletcher, Alexandria M. Chan

Mechanistic Analysis of an Extracellular Signal–Regulated Kinase 2–Interacting Compound that Inhibits Mutant BRAF-Expressing Melanoma Cells by Inducing Oxidative Stress

Journal of Pharmacology and Experimental Therapeutics(2020)10.1124/jpet.120.000266

N/A

0DataRank · unranked

8 citations

Weiliang Huang, Ramin Samadani, Bryan Mackowiak, Garrick Centola, Lijia Chen +6 more

Nanotherapy delivery of c-myc inhibitor targets Protumor Macrophages and preserves Antitumor Macrophages in Breast Cancer

Theranostics(2020)10.7150/thno.44523

N/A

0DataRank · unranked

41 citations

Michael H. Ross, Francesca Fontana, Xinming Su, Ariel Gabay, Gregory C. Fox +12 more

Orthogonal targeting of osteoclasts and myeloma cells for radionuclide stimulated dynamic therapy induces multidimensional cell death pathways

Theranostics(2021)10.7150/thno.60757

N/A

0DataRank · unranked

11 citations

Matthew Mixdorf, Lynne Marsala, Julie L. Prior, Xiaoxia Yang, Grace Cui +6 more

Scaffold hopping from indoles to indazoles yields dual MCL-1/BCL-2 inhibitors from MCL-1 selective leads

RSC Medicinal Chemistry(2022)10.1039/d2md00095d

N/A

0DataRank · unranked

16 citations

Christopher C. Goodis, Nathan G. Bowen, Wenbo Yu, Gregory E.A. Vickers, Paul T. Wilder +3 more

Recent applications of covalent chemistries in protein–protein interaction inhibitors

RSC Medicinal Chemistry(2022)10.1039/d2md00112h

N/A

0DataRank · unranked

15 citations

Christopher C. Goodis, Elie G. Pommier, Steven Fletcher, Alexandria M. Chan

1‐Sulfonylated 1,2,3,4‐tetrahydroquinoline‐6‐carboxylic acids as simple, readily‐accessible MCL‐1 inhibitors

Drug Development Research(2022)10.1002/ddr.22004

N/A

0DataRank · unranked

4 citations

Alexandria M. Chan, Paul T. Wilder, Steven Fletcher, Lijia Chen

Multimodal nanoparticle‐containing modified suberoylanilide hydroxamic acid polymer conjugates to mitigate immune dysfunction in severe inflammation

Bioengineering & Translational Medicine(2023)10.1002/btm2.10611

N/A

0DataRank · unranked

9 citations

Andrea L. Cottingham, Shruti Dharmaraj, Jacob R. Shaw, Jackline Joy Lasola, Christopher C. Goodis +3 more

The polypharmacy combination of the BCL-2 inhibitor venetoclax (VEN) and the FLT3 inhibitor gilteritinib (GIL) is more active in acute myeloid leukemia cells than novel polypharmacologic BCL-2/FLT3 VEN–GIL hybrid single-molecule inhibitors

European Journal of Medicinal Chemistry(2024)10.1016/j.ejmech.2024.117190

N/A

0DataRank · unranked

7 citations

Christian Eberly, Alexandria M. Chan, Minjung Kim, Brandon D. Lowe, Curt I. Civin +2 more

First-in-class mitogen-activated protein kinase (MAPK) p38α: MAPK-activated protein kinase 2 dual signal modulator with anti-inflammatory and endothelial-stabilizing properties

Journal of Pharmacology and Experimental Therapeutics(2024)10.1124/jpet.124.002281

N/A

0DataRank · unranked

5 citations

Kari Ann Shirey, Katerina N. Lugkey, Wendy Luo, Ritu Lal, Adam Galan +12 more

Histone deacetylase (HDAC) inhibitor specificity determinants are preserved in a class of dual HDAC/non-covalent proteasome inhibitors

Bioorganic & Medicinal Chemistry(2024)10.1016/j.bmc.2024.117680

N/A

0DataRank · unranked

6 citations

Ashley Mitchell, Lena Grogan, Paul Shapiro, Steven Fletcher, Alexandria M. Chan

Augmenting the Anti‐Leukemic Activity of the BCL‐2 Inhibitor Venetoclax Through Its Transformation Into Polypharmacologic Dual BCL‐2/HDAC1 and Dual BCL‐2/HDAC6 Inhibitors

Drug Development Research(2025)10.1002/ddr.70084

N/A

0DataRank · unranked

5 citations

Christian Eberly, Brandon Drennen, Christopher C. Goodis, Zoe Wuyts, Curt I. Civin +2 more

Rationally Designed Polypharmacology: α‐Helix Mimetics as Dual Inhibitors of the Oncoproteins Mcl‐1 and HDM2

ChemMedChem(2020)10.1002/cmdc.202000278

N/A

0DataRank · unranked

14 citations

Brandon Drennen, Maryanna E. Lanning, Samuel Hughes, Rebecca Rothhaas, Paul T. Wilder +3 more

First-in-Class Potent, Dual HDAC6/Proteasome Inhibitors Lacking a Hydroxamic Acid Motif: Discovery of Novel Anti-Multiple Myeloma Agents

ACS Medicinal Chemistry Letters(2025)10.1021/acsmedchemlett.5c00500

N/A

0DataRank · unranked

3 citations

Brandon D. Lowe, Andrea L. Cottingham, Daniel Van Eker, Asaminew H. Aytenfisu, Jace W. Jones +4 more